Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $245,760.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 12,000 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $20.48, for a total transaction of $245,760.00. Following the completion of the sale, the chief operating officer now owns 77,363 shares in the company, valued at $1,584,394.24. This represents a 13.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, February 10th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock traded down $0.16 during midday trading on Monday, reaching $20.05. 658,920 shares of the company's stock were exchanged, compared to its average volume of 464,078. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.87 and a 52 week high of $28.15. The stock's 50-day simple moving average is $21.07 and its 200 day simple moving average is $21.42. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -143.20 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. During the same quarter last year, the firm earned $0.35 earnings per share. The business's revenue for the quarter was up 46.9% compared to the same quarter last year. Research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP bought a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $1,192,000. JPMorgan Chase & Co. bought a new position in Kiniksa Pharmaceuticals during the third quarter worth $4,997,000. SG Americas Securities LLC acquired a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at $355,000. Charles Schwab Investment Management Inc. boosted its position in Kiniksa Pharmaceuticals by 36.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock valued at $2,414,000 after acquiring an additional 32,393 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Kiniksa Pharmaceuticals during the 4th quarter worth about $3,955,000. 53.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

KNSA has been the subject of several research analyst reports. Wedbush reiterated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.